Clinical Trial Update: Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating whether adding elacestrant to olaparib improves outcomes in patients with HR+/HER2- advanced or metastatic breast cancer; the stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Elacestrant (elacestrant)
• Olaparib (Olaparib)

Snippet

Sponsor: GBG Forschungs GmbH | Conditions: Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced or Metastatic Breast Cancer | Phase 2 | Status: RECRUITING